Managed access for eltrombopag in serious conditions
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy, Infections clinical trials.
This program provides access to an investigational medication called eltrombopag for people with serious or life-threatening conditions who have no other good treatment options. It is only available through a doctor's formal request and is not part of a clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor must formally request the medication for you.
- Your condition must be serious or life-threatening, with no other good treatment options.
- You must not be able to join or continue in a clinical trial.
- The likely benefit to you must outweigh the risks of the treatment.
- The request must comply with local laws and the manufacturer's rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program lets people with serious or life-threatening conditions get access to a medicine called ruxolitinib when they have no other good options and cannot join a clinical trial. It is a special access or compassionate use program, so your doctor must request it for you.
This program provides access to an experimental medicine called ianalumab for people with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. Your doctor must request this medicine for you, and the company (Novartis) will review each request individually.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This program lets doctors request an unapproved drug for patients with serious, life-threatening diseases when no other good options exist. It's a way to get the medicine outside of a clinical trial.
This trial gives people with serious diseases access to a special cell therapy (a treatment made from your own immune cells) when they have no other options. It's a 'compassionate use' program, meaning the drug is available outside of a clinical trial if you meet certain conditions.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.